$SILO Silo Pharma Advances Psychedelic Patent Port
Post# of 137
(Total Views: 169)
Posted On: 08/25/2021 9:18:13 AM
$SILO Silo Pharma Advances Psychedelic Patent Portfolio
https://www.globenewswire.com/news-release/20...folio.html
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these PCT applications relates to the continued research and development that Silo Pharma has continued to undertake.” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are excited to have taken this important next step to protect our intellectual property.”
These three PCT applications title listed below along with Silo Pharma’s granted IP expands the potential addressable patient population that needs unique patient-focused therapeutics.
CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN
The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.
https://www.globenewswire.com/news-release/20...folio.html
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these PCT applications relates to the continued research and development that Silo Pharma has continued to undertake.” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are excited to have taken this important next step to protect our intellectual property.”
These three PCT applications title listed below along with Silo Pharma’s granted IP expands the potential addressable patient population that needs unique patient-focused therapeutics.
CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN
The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.
(0)
(0)